Antistaphylococcal discovery pipeline; where are we now?
Language English Country France Media print-electronic
Document type Journal Article, Review
PubMed
38219657
DOI
10.1016/j.ejmech.2023.116077
PII: S0223-5234(23)01044-9
Knihovny.cz E-resources
- Keywords
- Antibody, Antistaphylococcal, Clinical trial, Drug discovery, Small molecules,
- MeSH
- Anti-Bacterial Agents * pharmacology therapeutic use MeSH
- Humans MeSH
- Peptides therapeutic use MeSH
- Staphylococcal Infections * drug therapy MeSH
- Staphylococcus aureus MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Anti-Bacterial Agents * MeSH
- Peptides MeSH
The serious spread of antibiotic-resistant Staphylococcal aureus strains is alarming. This is reflected by the measures governments and health-related bodies are offering to ease antibiotic drug development. Finding new active agents, preferably with novel mechanism of action, or even finding new targets for drug development are essential. In this review, we summarize the current status of novel antistaphylococcal agents undergoing clinical trials. We mainly discuss antistaphylococcal small molecules and peptides in the text with a special focus on their chemistry, while antistaphylococcal immunotherapy (antibodies) are mentioned in a summative table. This review shall serve as a summary that influences future synthetic efforts in the antistaphyloccocals development field.
References provided by Crossref.org